Serina Therapeutics Inc.

NYSE: SER · Real-Time Price · USD
5.95
0.00 (0.00%)
At close: Jun 06, 2025, 3:44 PM
6.49
9.08%
After-hours: Jun 06, 2025, 05:46 PM EDT

Company Description

Serina Therapeutics, Inc., a biotechnology company, develops drugs to treat neurological diseases and pain.

Its lead product candidate is SER 252, a POZ conjugate for the treatment of Parkinson's disease.

The company also develops SER 227 for long-acting pain relief; SER 214 to treat Parkinson's disease; and SER 228 for the treatment of epilepsy.

In addition, it develops POZ technology in lipid nanoparticle delivered ribonucleic acid vaccines for infectious diseases.

Serina Therapeutics, Inc. was founded in 2006 and is based in Huntsville, Alabama.

Serina Therapeutics Inc.
Serina Therapeutics Inc. logo
Country United States
IPO Date Jan 21, 2000
Industry Biotechnology
Sector Healthcare
Employees 12
CEO Steven A. Ledger

Contact Details

Address:
601 Genome Way
Huntsville, Alabama
United States
Website https://serinatherapeutics.com

Stock Details

Ticker Symbol SER
Exchange NYSE
Fiscal Year n/a
Reporting Currency USD
CIK Code 0001708599
CUSIP Number 81751A108
ISIN Number US81751A1088
Employer ID 82-1436829
SIC Code 2834

Key Executives

Name Position
Steven A. Ledger Chief Executive Officer & Director
Gregory S. Curhan Chief Financial Officer
Dr. Balkrishan Gill Ph.D. Executive Chairman
Dr. J. Milton Harris Ph.D. Co-Founder, Director Emeritus & Chair of Scientific Advisory Board
Dr. Randall W. Moreadith M.D., Ph.D. Chief Development Officer
Dr. Srini Tenjarla Senior Vice President of Chemistry, Manufacturing & Controls and Formulation

Latest SEC Filings

Date Type Title
May 22, 2025 8-K Current Report
May 08, 2025 8-K Current Report
May 08, 2025 10-Q Quarterly Report
Apr 29, 2025 8-K Current Report
Apr 28, 2025 EFFECT Filing
Apr 28, 2025 424B5 Filing
Apr 24, 2025 CORRESP Filing
Apr 23, 2025 UPLOAD Filing
Apr 18, 2025 S-3 Filing
Apr 15, 2025 8-K Current Report